Innovation

The strange and special case of epinephrine

The biotech social contract stipulates that all drugs must…

Direct-to-Consumer (DTC) advertising: misnamed, misunderstood, and underappreciated

Let’s Throw a Patent-Burning Party

When a drug goes generic, it’s as if society has paid off a…

Hard Negotiating Tactics: Compulsory Licensing and Willingness to Deny

The Favors They Do Us: Charging Less in Other Countries Makes Drugs More Affordable in America

Why wait for generics? In praise of me-too drugs

Peter Kolchinsky, Ph.D

False Heroes — How PBMs Add Insult to the Injury of Insurance Cost-Sharing

America’s Social Contract with the Biopharmaceutical Industry

What happens when a drug won’t go generic?

Peter Kolchinsky, Ph.D.

This is the second in a series of articles that aim to define the biopharmaceutical industry’s social contract with America, to examine practices that deviate from that contract, and to propose refinements…